Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$5.89 USD
+0.36 (6.51%)
Updated Oct 14, 2025 04:00 PM ET
After-Market: $5.88 -0.01 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Recursion Pharmaceuticals, Inc.'s return on equity, or ROE, is -76.09% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that RXRX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
RXRX 5.89 +0.36(6.51%)
Will RXRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Other News for RXRX
Is RXRX building bullish momentum? Non-ADX 1,2,3,4 Bullish shows up after climbing 3.95%
Recursion Pharmaceuticals call volume above normal and directionally bullish
Recursion Pharmaceuticals call volume above normal and directionally bullish
Is RXRX setting up for a drop? Fell Below 200 Day Moving Average shows up after tumbling 9.98%
200 Day Moving Average Support appears for RXRX after 2.96% move